2.435

0.41% -0.005

Inhibikase Therapeutics Inc (IKT)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.43

Offen:

$2.43

24-Stunden-Volumen:

117.09K

Relative Volume:

0.16

Marktkapitalisierung:

$339.07M

Einnahmen:

$79,600

Nettoeinkommen (Verlust:

$-48.26M

KGV:

-4.9472

EPS:

-0.4922

Netto-Cashflow:

$-28.24M

1W Leistung:

-3.20%

1M Leistung:

-2.02%

6M Leistung:

+28.04%

1J Leistung:

+44.91%

1-Tages-Spanne:

$2.3852

$2.45

1-Wochen-Bereich:

$2.3852

$2.61

52-Wochen-Spanne:

$1.33

$2.61

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Firmenname

Inhibikase Therapeutics Inc

Sektor

Healthcare (1087)

Branche

Biotechnology (606)

Telefon

(302) 295-3800

Adresse

1000 N. WEST STREET, SUITE 1200, WILMINGTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IKT Inhibikase Therapeutics Inc	2.43	339.07M	79,600	-48.26M	-28.24M	-0.4922
VRTX Vertex Pharmaceuticals Inc	521.93	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	801.54	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,001.82	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.75	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.48	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-04	Eingeleitet	Ladenburg Thalmann	Buy
2026-01-21	Eingeleitet	BofA Securities	Buy
2025-12-26	Eingeleitet	H.C. Wainwright	Buy
2025-12-11	Eingeleitet	Cantor Fitzgerald	Overweight
2025-02-12	Herabstufung	H.C. Wainwright	Buy → Neutral

Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten

Sep 08, 2026

Inhibikase advances IKT-001 in pivotal PAH Phase 3 - TipRanks

Sep 08, 2026

Inhibikase updates corporate presentation, highlights Phase 3 IKT-001 program and timelines - TradingView

Sep 08, 2026

Inhibikase (NASDAQ: IKT) tests PAH pill in pivotal global trial - Stock Titan

Sep 08, 2026

Sep 04, 2026

IKT News | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill

Sep 04, 2026

Sep 03, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Sep 03, 2026

Sep 01, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Stock Price Down 4.1%What's Next? - MarketBeat

Sep 01, 2026

Aug 26, 2026

Inhibikase Therapeutics Appoints Deloitte & Touche LLP After Dismissing CohnReznick LLP as Auditor - kalkinemedia.com

Aug 26, 2026

Aug 21, 2026

Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current SessionFibonacci Extension - siam.in

Aug 21, 2026

Aug 19, 2026

Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the CloseFree Cash Flow Trends - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Inhibikase Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026

Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo

Aug 18, 2026

Aug 17, 2026

Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Shakeout Pattern - vinanet.vn

Aug 17, 2026

Aug 16, 2026

Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 ResistanceReversal Setup Alerts - vinanet.vn

Aug 16, 2026

IKT Q1 2026 Earnings: Narrower Loss of $0.10 Per Share Beats Estimates as Pre-Revenue Biotech Holds SteadyEPS Surprise History - vinanet.vn

Aug 16, 2026

Aug 14, 2026

Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan

Aug 14, 2026

Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan

Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026

Aug 13, 2026

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan

Aug 13, 2026

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 13, 2026

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks

Aug 13, 2026

Aug 12, 2026

Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Aug 11, 2026

Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus

Aug 11, 2026

LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 11, 2026

Inhibikase grants $2.03 stock options to seven new hires - scanx.trade

Aug 11, 2026

Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade

Aug 11, 2026

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 11, 2026

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance

Aug 11, 2026

Aug 10, 2026

Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 09, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Aug 09, 2026

Aug 02, 2026

Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Aug 02, 2026

Aug 01, 2026

Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et

Aug 01, 2026

Jul 31, 2026

Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView

Jul 31, 2026

Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo

Jul 31, 2026

18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan

Jul 31, 2026

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada

Jul 31, 2026

Jul 29, 2026

Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et

Jul 29, 2026

Jul 28, 2026

Inhibikase Therapeutics (IKT) Slips 1% as Shares Test Key Support at $2.21RVOL Breakout - dars.gov.et

Jul 28, 2026

Jul 27, 2026